DSM-Firmenich AG
DSFIR: XAMS (NLD)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| qBx | LOCK|^c | LOCK|zMr<&S |
DSM-Firmenich Earnings: Restructuring Noise Masks Strong Underlying Business
DSM-Firmenich reported 2% organic sales growth in the fourth quarter on a comparable basis, incorporating the announced divestment of its animal nutrition and health division. The company did not provide guidance for 2026, which contributed to an 8% share price decline on Feb. 12 amid uncertainty.
